Peptide Schedule
Bronchogen4 residuesAEDLEach bubble = one amino acid. Size = residue mass. Color = chemical class.Bronchogen Dosage Calculator
Bronchogen is a synthetic tetrapeptide bioregulator consisting of Ala-Glu-Asp-Leu (AEDL), developed through Professor Vladimir Khavinson's bioregulation research program at the Institute of Bioregulation and Gerontology in St.
10mcg · Daily
Summary: Add 0mL BAC water to your 20mg vial. Draw to < 0.1 units on a U-100 syringe for a 10mcg dose. This vial will last 0 doses.
Cycle Planner
Bronchogen Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~0.5-2 hours (estimated, tetrapeptide)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Bronchogen Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mg | Daily |
| Moderate | 20mg | Daily |
| Aggressive | 20mg | 2x Daily |
Note: Bronchogen (AEDL) is a synthetic tetrapeptide bioregulator developed through Khavinson's peptide bioregulation program, targeting bronchial and pulmonary tissue. It's typically available as oral capsules (20 mg) or lyophilized powder for research. Standard protocols call for 1-2 capsules daily over 20-30 day courses, repeated every 4-6 months. As a short-chain peptide, it demonstrates oral bioavailability when formulated in enteric-coated capsules.
About Bronchogen
Bronchogen is a synthetic tetrapeptide bioregulator consisting of Ala-Glu-Asp-Leu (AEDL), developed through Professor Vladimir Khavinson's bioregulation research program at the Institute of Bioregulation and Gerontology in St. Petersburg. It belongs to the "cytogen" class of synthesized short peptides designed to interact with DNA in a tissue-specific manner, targeting bronchial epithelium and pulmonary tissue. In bronchial tissue specifically, Bronchogen has been shown to regulate genes governing epithelial differentiation (NKX2-1, FOXA1, FOXA2), mucin production (MUC4, MUC5AC), and surfactant protein expression (SFTPA1). It also modulates levels of key proteins including Ki67, p53, Mcl-1, and NOS-3, with particularly pronounced effects observed in aged cell cultures. Animal studies using rat models of chronic obstructive pulmonary disease have produced encouraging results. One-month courses of Bronchogen reversed bronchial epithelial remodeling, restored ciliated cell populations, normalized inflammatory cytokine profiles, and increased secretory IgA and surfactant protein B levels. In vitro work has demonstrated the peptide's ability to stabilize DNA structure, increasing DNA melting temperature by approximately 3.1 degrees C through binding in the major groove at N7 guanine positions. Current evidence comes exclusively from preclinical research — animal models, cell cultures, and molecular studies. No controlled human clinical trials have been conducted, and the peptide isn't approved for medical use in any Western jurisdiction.